Dostarlimab before surgery for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at how well the immunotherapy drug dostarlimab works before surgery in patients with a specific type of advanced rectal cancer that has DNA repair problems (called dMMR/MSI-H). The goal is to see if it is safe and effective in the real world.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage II or stage III rectal cancer that has not spread to other parts of the body.
- You have a type of cancer called dMMR or MSI-H, which means your cancer cells have trouble fixing DNA.
- You have not had any previous treatment (surgery, chemotherapy, or radiation) for this rectal cancer.
- You are willing and able to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (dostarlimab) to standard chemotherapy after the usual chemoradiation helps treat locally advanced rectal cancer better than chemotherapy alone. Immunotherapy helps your immune system fight cancer cells, and may improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy and bevacizumab before surgery can shrink rectal tumors and improve outcomes. It is designed for people with locally advanced rectal cancer that has not spread to distant organs, and the treatment is given as a first step before the main surgery.
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
This study tests dostarlimab given before surgery for stage II or III colon cancer that has a specific DNA repair defect. It aims to shrink or control the cancer so that some people may be able to skip surgery if the results are good.
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.